Related Experiment Videos
[Giant-cell tumor of the bone]
Miklós Szendröi1, Imre Antal, János Kiss
1Semmelweis Egyetem, Altalános Orvostudományi Kar, Ortopédiai Klinika, Budapest.
Orvosi Hetilap
|July 18, 2003
Summary
Giant-cell tumor of bone (GCT) is an unpredictable bone lesion. While aggressive, effective treatments achieve high cure rates, emphasizing joint-sparing surgery and adjuvant therapies to minimize recurrence.
Area of Science:
- Orthopedic Oncology
- Bone Pathology
- Surgical Oncology
Context:
- Giant-cell tumor of bone (GCT) presents as an aggressive benign, yet potentially malignant, bone lesion.
- Its biological behavior is unpredictable, with increasing aggressivity often linked to recurrences.
- Factors influencing GCT aggressivity include mitotic activity, metalloproteinase expression, and oncogene alterations.
Purpose:
- To outline the characteristics and treatment strategies for giant-cell tumors of bone.
- To emphasize the importance of joint-sparing surgical techniques and adjuvant therapies in managing GCT.
- To discuss the role of radiotherapy in specific challenging locations.
Summary:
- Approximately 80% of GCTs follow a benign course, but local recurrence rates range from 10-50%.
- Malignant transformation occurs in about 10% of recurrent GCTs, with a 1-4% risk of pulmonary metastases.
- Despite recurrence potential, adequate treatment yields a 96-98% cure rate for GCT patients.
Impact:
- Joint-sparing curettage with adjuvants (e.g., bone cement, phenol) is crucial for reducing GCT recurrence.
- Surgical resection is reserved for extensive joint destruction or confirmed malignancy.
- Radiotherapy, with modern equipment, minimizes secondary malignant transformation and is recommended for surgically difficult sites.